Abstract
Objective
The purpose of this secondary analysis was to describe the prevalence of anxiety, depression, and perceived stress among women newly diagnosed with breast cancer and the impact of baseline and changes in anxiety on cognitive functioning following exercise and mind-body prehabilitation interventions.
Methods
The sample consisted of 49 women with newly diagnosed breast cancer (stages I–III) who planned to undergo breast cancer surgery at two academic cancer centers. Participants were randomized to receive an exercise or mind-body prehabilitation intervention between the time of diagnosis and breast cancer surgery. Participants completed self-report measures of anxiety, depression (HADS), perceived stress, and cognitive functioning (EORTC-QLQ-C30) at study enrollment and prior to surgery (post-intervention). The relationships between change in cognitive functioning and change in anxiety among all participants were estimated using linear regression modeling.
Results
A significant proportion of women with newly diagnosed breast cancer had clinically significant anxiety (34.0%). Greater anxiety was moderately associated with worse cognitive functioning (r = –0.33) at baseline. Linear modeling found that changes in cognitive functioning and anxiety were inversely related: Each one-unit decrease in anxiety was associated with a two-unit improvement in cognitive function (p = .06).
Conclusions
Anxiety was common in women with newly diagnosed breast cancer and was related to worse cognitive functioning. Assessment of anxiety at the time of diagnosis may allow for earlier anxiety management and subsequent improvement in cognitive functioning.
Trial Registration:
Acknowledgment
The authors would like to acknowledge Laura Shockro and Nancy Campbell for their assistance with data collection and implementation of the study interventions.
Disclosure statement
EW has received personal fees (consulting) from Athenex, Carrick Therapeutics, G1 Therapeutics, Genentech/Roche, Genomic Health, GSK, Jounce, Leap, Lilly, Novartis, Seattle Genetics, Syros, and Zymeworks; has received research funding from Astra Zeneca and Genentech/Roche; and serves on the scientific advisory board of Leap. RK has received personal fees (consulting) from Fors Marsh Group, Osmol Therapeutics, Inc., and the Comprehensive and Integrative Medicine Institute. No potential conflict of interest was reported by the authors.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.